The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2019-3941
Date:	17 July 2019
Product Name:	Risperidone/ Paliperidone palmitate/Paliperidone
Therapeutic Area:	Neuroscience
Product Class:	Atypical antipsychotics
Condition(s) Studied:	Schizophrenia
Protocol Number(s) and Title(s):	**Paliperidone palmitate/Paliperidone:** NCT01299389 PALM-JPN-4 NCT00518323 R076477PSZ3001 NCT01009047 R076477PSZ3003 NCT00397033 R076477SCA3001 NCT00412373 R076477SCA3002 NCT00334126 R076477SCH3015 NCT00085748 R076477-SCH-302 NCT00078039 R076477-SCH-303 NCT00077714 R076477-SCH-304 NCT00083668 R076477-SCH-305 NCT00524043 R076477-SCH-4012 NCT00210717 R092670PSY3002 NCT00210548 R092670PSY3003 NCT00101634 R092670PSY3004 NCT00589914 R092670PSY3006 NCT00590577 R092670PSY3007 NCT00074477 R092670SCH201 **Risperidone:** NCT00249132 RIS-INT-3 NCT00088075 RIS-SCH-302 N/A RIS-USA-1 (RIS-USA-9001) NCT00253136 RIS-USA-121 NCT00034749 RIS-USA-231 N/A RIS-USA-72

Part 2: Data Availability	
Question:	**Response:**
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	

The YODA Project
Research Proposal Due Diligence Assessment

The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	N/A
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	N/A
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes
Part 4: Proposal Review	
Question:	**Response:**
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	